Exozymes Inc (EXOZ) Stock Price, Quote & News

Company Profile

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 626 415 1488

Website: www.exozymes.com

Address:

750 Royal Oaks Drive, Suite 106, Monrovia, United States

Slack_Capital Jul. 25 at 11:59 PM

$EXOZ @eXoZymes receives grant funding to build an AI model that predicts how its cell-free enzymatic pathways will perform under different conditions. The ambition is to computationally determine optimal cell-free parameters (temperature, pH, concentrations, enzyme ratios) and estimate performance outputs like synthesis yields, titres and rates. The team has already developed an AI model to optimise an enzyme's design in a cell-free environment... and this next step extends the company's capability to predict full pathway performance across process conditions. If the team can successfully design such a model, this would be a monumental breakthrough, further reducing eXoZymes' compound development timeframes and DBTL costs. Eventually, this could lead the company to develop and spin-out multiple high-value, IP-protected compounds every single year. https://exozymes.com/blog/genesis-mission-2026

0 · Reply

B2iDigital Jul. 24 at 9:57 PM

eXoZymes (Nasdaq: $EXOZ ) is among the first projects selected for the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together national laboratories, universities, companies, and nonprofit organizations to accelerate scientific discovery. eXoZymes will work with Lawrence Berkeley National Laboratory to build AI-powered digital twins for its cell-free biomanufacturing platform. eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes The project extends the company’s AI work from enzyme engineering into manufacturing: • With Berkeley Lab, eXoZymes will develop hybrid digital twins that combine enzyme kinetics, reactor physics, and machine learning to identify optimal operating conditions before lab validation • The award provides access to the DOE Genesis Mission Platform: advanced AI models, AI agents, and high-performance computing • Subject to DOE award negotiations, the project is expected to carry about $747,000 in total funding, including about $147,000 for eXoZymes “We believe the next generation of biomanufacturing will be built at the intersection of artificial intelligence and digital insights into biology,” said Michael Heltzen, Chief Executive Officer of eXoZymes. Read the full release: https://exozymes.com/blog/genesis-mission-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

B2iDigital Jul. 23 at 4:01 PM

eXoZymes (Nasdaq: $EXOZ ) frames itself as a repeatable engine for unlocking molecule classes. In a Webull webinar, Chief Commercial Officer Damien Perriman put cannabinoids forward as the next class after NCT. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "This is not a single product company. It's a repeatable system for unlocking entire classes of molecules," Perryman told investors. Also from the presentation: • NCT is the first proof point and cannabinoids are the second, with cannabinoid receptors present on nearly every cell in the body • That reach spans metabolic, inflammatory, and neurological conditions, where access to rare cannabinoids has long been the bottleneck • eXoZymes says it can now produce rare and entirely new cannabinoids without intoxicating components, optimized toward specific therapeutic objectives Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

B2iDigital Jul. 17 at 9:10 PM

A platform that works in the lab is not yet a business. In a Webull webinar, eXoZymes (Nasdaq: $EXOZ ) pointed to a scale-up run it says clears that bar. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 Perryman framed the milestone directly: "Many technologies work in the lab, but many also fail at scale. What we've demonstrated here is that the system translates from concept to industrial conditions, and that's what turns this from a science into a viable business." The webinar detailed the run: • The company ran a 100-liter pilot at the end of last year, reporting 99% conversion of raw material to target product and 99.6% purity • The run took place at a third party after eXoZymes tech-transferred its process, operating conditions, and enzyme cascades • Management called this an operational process rather than a theoretical one, and an inflection point for investors Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

_ivan Jul. 16 at 6:48 AM

$ARKG $DNA $DNLI $EXOZ $TWST

0 · Reply

B2iDigital Jul. 14 at 5:15 PM

eXoZymes (Nasdaq: $EXOZ ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company's first proof point. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "It is fundamentally different from GLP-1 drugs," Perryman said. "GLP-1s reduce appetite, whereas NCT and its activation of HNF4 alpha improves mitochondrial biogenesis and mitochondrial activity, essentially improving how the body burns fat." From the same segment: • NCT activates HNF4 alpha, a master metabolic control switch, rather than acting on a single downstream symptom • In controlled preclinical models on identical diets, eXoZymes reported 30% to 40% less weight gain in the mouse population • The company also observed improved mitochondrial function and reduced liver fat, consistent with hitting a central regulatory pathway Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

B2iDigital Jul. 8 at 11:59 PM

eXoZymes (Nasdaq: $EXOZ ) makes its case for cell-free biomanufacturing, the approach it says sidesteps where whole-cell synthetic biology has repeatedly failed to scale. Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perriman laid out why the company removed the cell from the equation entirely. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "Engineered cells have become a boulevard of broken dreams on Wall Street, and eXoZymes found a way to navigate around this problem," said Damien Perryman, Chief Commercial Officer of eXoZymes. In the webinar, Perryman also covered: • Cells evolved to survive, not to manufacture, so whole-cell systems carry biological noise, toxicity limits, and regulatory complexity into production • eXoZymes isolates the enzymes, engineers them with AI, and runs them outside the cell to produce target molecules cleanly and at scale • The result behaves more like precision chemistry than a biological production system, inspired by biology's own catalysts Watch the full webinar: youtube.com/watch?v=OmH3TaaMT20&feature=youtu.be eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

Slack_Capital Jul. 3 at 11:40 PM

$EXOZ Reminder that we've set up an eXoZymes discord group!

0 · Reply

B2iDigital Jun. 25 at 9:21 PM

eXoZymes (Nasdaq: $EXOZ) secures $2 million NIH grant, expanding its proprietary pharmaceutical biosolutions pipeline into non-intoxicating cannabinoids. Federal research funding extends eXoZymes’ cell-free platform further into drug discovery. eXoZymes Inc. (Nasdaq: EXOZ) has received a Notice of Award from the National Institutes of Health for a roughly $2 million Phase IIB SBIR grant to produce rare cannabinoids and engineer cannabinoid analogs for pharmaceutical evaluation. The award adds a second biosolution to the pipeline alongside NCT, expands the company’s portfolio of proprietary pharmaceutical assets, and lifts total non-dilutive funding awarded to eXoZymes and its predecessor programs to approximately $19.7 million. The two-year program begins July 1, 2026. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Michael Heltzen, CEO of eXoZymes, commented: “This is a key milestone that demonstrates our repeatable development engine of future licensing and partnering opportunities - a key feature in creating additional proprietary molecules without diluting shareholders.” From the announcement: • The grant supports work to build cannabinoid cyclase expression systems, widen the analog range, and run preclinical receptor-binding evaluation of the cannabinoid library • It arrives as the US minor cannabinoids market is forecast to grow from $11.5 billion in 2023 to $33.3 billion by 2030 See the full release: https://exozymes.com/blog/grant-cannabinoid-analogs eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

prismmarketview Jun. 25 at 3:07 PM

$EXOZ got a new NIH Phase IIB SBIR grant worth ~$2.03M to support rare cannabinoid and cannabinoid‑analog programs, starting July 1, 2026. Total non‑dilutive funding now sits near $19.7M. #EXOZ #NIH #biotech #AI https://prismmarketview.com/nih-cash-fuels-exozymes-push-into-next-gen-cannabinoids/

0 · Reply

eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing

2026-07-15T13:46:15.000Z - 14 days ago

eXoZymes Inc trading resumes

2026-07-15T13:41:41.000Z - 14 days ago

eXoZymes Inc trading halted, volatility trading pause

Jun 24, 2026, 4:10 PM EDT - 5 weeks ago

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

Jun 17, 2026, 4:10 PM EDT - 6 weeks ago

eXoZymes Inc. Announces Closing of $6 Million Public Offering

2026-06-08T13:20:53.000Z - 7 weeks ago

eXoZymes prices 592,270 shares at $18.00 in public offering

Jun 8, 2026, 9:00 AM EDT - 7 weeks ago

eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants

May 14, 2026, 4:00 PM EDT - 2 months ago

eXoZymes Quarterly report: Q1 2026

2026-05-07T19:15:17.000Z - 2 months ago

eXoZymes announces graduation from Shell GameChanger Accelerator

May 7, 2026, 9:05 AM EDT - 2 months ago

eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program

May 7, 2026, 7:00 AM EDT - 3 months ago

eXoZymes Slides: Investor presentation

Apr 10, 2026, 9:10 AM EDT - 3 months ago

eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast

Apr 10, 2026, 7:00 AM EDT - 3 months ago

eXoZymes Slides: Investor presentation

Apr 1, 2026, 7:00 AM EDT - 4 months ago

eXoZymes Slides: Investor presentation

Mar 31, 2026, 5:30 PM EDT - 4 months ago

eXoZymes Earnings Call Transcript: Q4 2025

Mar 31, 2026, 5:30 PM EDT - 4 months ago

eXoZymes Earnings release: Q4 2025

Mar 31, 2026, 5:30 PM EDT - 4 months ago

eXoZymes Annual report: Q4 2025

Mar 31, 2026, 4:20 PM EDT - 4 months ago

eXoZymes Provides Fourth Quarter and Full Year 2025 Update

Mar 31, 2026, 7:00 AM EDT - 4 months ago

eXoZymes Slides: Investor presentation

Mar 25, 2026, 4:10 PM EDT - 4 months ago

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

2026-03-18T13:15:28.000Z - 4 months ago

eXoZymes announces validation milestone for its biomanufacturing platform

Mar 18, 2026, 9:10 AM EDT - 4 months ago

Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

Mar 12, 2026, 4:15 PM EDT - 4 months ago

eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

Feb 10, 2026, 4:20 PM EST - 6 months ago

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

Jan 29, 2026, 7:45 PM EST - 6 months ago

eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run

2026-01-16T20:55:43.000Z - 6 months ago

eXoZymes files $50M mixed securities shelf

Jan 16, 2026, 7:00 AM EST - 6 months ago

eXoZymes Registration statement: Registration Filing

Dec 11, 2025, 4:10 PM EST - 8 months ago

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

2025-11-19T15:40:17.000Z - 9 months ago

eXoZymes Inc trading resumes

2025-11-19T15:35:09.000Z - 9 months ago

eXoZymes Inc trading halted, volatility trading pause

2025-11-18T16:35:49.000Z - 9 months ago

eXoZymes Inc trading resumes

2025-11-18T16:30:20.000Z - 9 months ago

eXoZymes Inc trading halted, volatility trading pause

Nov 13, 2025, 5:00 PM EST - 9 months ago

eXoZymes Earnings Call Transcript: Q3 2025

Nov 13, 2025, 5:00 PM EST - 9 months ago

eXoZymes Earnings release: Q3 2025

Nov 13, 2025, 5:00 PM EST - 9 months ago

eXoZymes Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

Nov 13, 2025, 4:15 PM EST - 9 months ago

eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff

Nov 10, 2025, 5:00 PM EST - 9 months ago

eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

Oct 30, 2025, 4:10 PM EDT - 9 months ago

CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference

Oct 29, 2025, 5:40 PM EDT - 9 months ago

CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference

2025-10-24T15:35:10.000Z - 9 months ago

eXoZymes Inc trading resumes

2025-10-24T15:30:20.000Z - 9 months ago

eXoZymes Inc trading halted, volatility trading pause

Oct 23, 2025, 4:50 PM EDT - 9 months ago

CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference

Sep 30, 2025, 4:10 PM EDT - 10 months ago

Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees

Aug 12, 2025, 5:00 PM EDT - 1 year ago

eXoZymes Earnings Call Transcript: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 1 year ago

eXoZymes Earnings release: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 1 year ago

eXoZymes Quarterly report: Q2 2025

Aug 12, 2025, 4:50 PM EDT - 1 year ago

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

Aug 7, 2025, 6:35 PM EDT - 1 year ago

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

2025-07-29T12:31:33.000Z - 1 year ago

eXoZymes achieves four grams of NCT with over 99% purity

Jul 29, 2025, 7:57 AM EDT - 1 year ago

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

Jul 22, 2025, 4:10 PM EDT - 1 year ago

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

2025-06-26T20:30:34.000Z - 1 year ago

eXoZymes announces role in $9.2M Meta-PURE initiative

Jun 26, 2025, 4:10 PM EDT - 1 year ago

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

Jun 23, 2025, 8:00 AM EDT - 1 year ago

eXoZymes Proxy statement: Proxy Filing

Jun 20, 2025, 8:00 AM EDT - 1 year ago

eXoZymes Proxy statement: Proxy Filing

May 16, 2025, 9:25 AM EDT - 1 year ago

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

May 12, 2025, 5:00 PM EDT - 1 year ago

eXoZymes Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

eXoZymes Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

eXoZymes Quarterly report: Q1 2025

May 12, 2025, 4:10 PM EDT - 1 year ago

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

May 7, 2025, 5:20 PM EDT - 1 year ago

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

May 6, 2025, 4:10 PM EDT - 1 year ago

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

Apr 21, 2025, 4:10 PM EDT - 1 year ago

Bringing clarity and precision to the cell-free space by introducing exozymes

Apr 10, 2025, 4:30 PM EDT - 1 year ago

BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

Apr 2, 2025, 4:30 PM EDT - 1 year ago

eXoZymes Earnings Call Transcript: Q4 2024

Apr 2, 2025, 4:30 PM EDT - 1 year ago

eXoZymes Annual report: Q4 2024

Apr 2, 2025, 4:30 PM EDT - 1 year ago

eXoZymes Earnings release: Q4 2024

2025-04-02T20:20:30.000Z - 1 year ago

eXoZymes appoints Damien Perriman chief commercial officer

Apr 2, 2025, 4:10 PM EDT - 1 year ago

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

Apr 2, 2025, 4:05 PM EDT - 1 year ago

eXoZymes Provides Fourth Quarter and Full Year 2024 Update

Mar 26, 2025, 5:00 PM EDT - 1 year ago

eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025

2025-03-17T17:45:05.000Z - 1 year ago

eXoZymes Inc trading resumes

2025-03-17T17:35:35.000Z - 1 year ago

eXoZymes Inc trading halted, volatility trading pause

2025-02-21T21:10:27.000Z - 1 year ago

eXoZymes president, chairman Hayat transitions out of roles

MDBH

Feb 21, 2025, 4:05 PM EST - 1 year ago

eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.

2025-02-19T14:40:31.000Z - 1 year ago

eXoZymes Inc trading resumes

2025-02-19T14:35:46.000Z - 1 year ago

eXoZymes Inc trading halted, volatility trading pause

Slack_Capital Jul. 25 at 11:59 PM

0 · Reply

B2iDigital Jul. 24 at 9:57 PM

1 · Reply

B2iDigital Jul. 23 at 4:01 PM

1 · Reply

B2iDigital Jul. 17 at 9:10 PM

1 · Reply

_ivan Jul. 16 at 6:48 AM

$ARKG $DNA $DNLI $EXOZ $TWST

0 · Reply

B2iDigital Jul. 14 at 5:15 PM

1 · Reply

B2iDigital Jul. 8 at 11:59 PM

1 · Reply

Slack_Capital Jul. 3 at 11:40 PM

$EXOZ Reminder that we've set up an eXoZymes discord group!

0 · Reply

B2iDigital Jun. 25 at 9:21 PM

1 · Reply

prismmarketview Jun. 25 at 3:07 PM

0 · Reply

topstockalerts Jun. 24 at 11:56 PM

eXoZymes shares rose in after-hours trading after the company announced it had received a $2.03 million NIH Phase IIB Small Business Innovation Research grant to advance its cannabinoid analog research program. The funding, which begins on July 1, 2026, will support the development of rare cannabinoids and engineered cannabinoid analogs using eXoZymes’ cell-free production platform. The grant includes approximately $1.03 million for the first budget period and $994,000 for the second year, subject to progress and funding availability. The program will focus on improving cannabinoid cyclase enzyme expression systems, expanding the range of cannabinoid analogs the company can produce, and conducting preclinical receptor-binding studies on its existing cannabinoid library. The award increases eXoZymes’ total non-dilutive funding to nearly $19.7 million. $EXOZ

0 · Reply

ClassiTrader Jun. 24 at 10:17 PM

$EXOZ

0 · Reply

ClassiTrader Jun. 24 at 5:34 PM

$EXOZ 👀

0 · Reply

B2iDigital Jun. 23 at 8:53 PM

eXoZymes (Nasdaq: $EXOZ ) Chief Commercial Officer Damien Perriman will present at Webull’s Biotech Sector webinar on June 25, alongside Envoy Medical and IN8bio. Damien Perriman, Chief Commercial Officer of eXoZymes Inc. (Nasdaq: EXOZ), will present at Webull’s Biotech Sector webinar on June 25 at 2:00 p.m. Eastern, part of the Webull Corporate Connect series that spotlights publicly traded biotech companies for investors. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 eXoZymes is a synthetic biology company that takes enzymes out of the living cell and runs them on their own to manufacture hard-to-make molecules for nutraceutical and pharmaceutical markets. The session gives investors a chance to hear directly from the company’s commercial leadership. • The webinar takes place June 25 at 2:00 p.m. Eastern, 11:00 a.m. Pacific, and registration is free with a Webull account • Perriman presents alongside Brent Lucas, Chief Executive Officer of Envoy Medical, and Will Ho, Chief Executive Officer and co-founder of IN8bio • Perriman leads commercial strategy at eXoZymes, whose cell-free platform uses AI-engineered enzymes to convert low-cost feedstocks into high-value compounds Register for the webinar: https://exozymes.com/blog/webulls-biotech-webinar-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

Slack_Capital Jun. 23 at 7:14 AM

$EXOZ The best way to understand @eXoZymes capital allocation strategy is to look at companies like ARM Holdings. ARM dominates the semiconductor industry by owning microchip architecture and never engaging in physical fabrication. Instead, ARM licenses its intellectual property to giants like Apple and Qualcomm, who handle production at foundries like TSMC. By remaining asset-light and focused on core R&D, ARM captures a staggering 97% gross margin on licensing fees and recurring royalties on every chip shipped. @eXoZymes runs a similar playbook adapted for biomanufacturing. Operating strictly as an R&D engine, the company designs enzymatic "architecture" for its innovative cell-free platform. Their proprietary biocatalytic pathways convert basic feedstocks into high-value nutraceutical and pharmaceutical analog compounds.

1 · Reply

B2iDigital Jun. 19 at 2:15 PM

eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids. A May 2026 investor presentation from eXoZymes (Nasdaq: $EXOZ ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.” The presentation also covered: • A platform the company says also extends to terpenes and flavonoids • A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes • A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies • Recognition in scientific and news publications and grant funding the company cites as validation Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

focafoca99 Jun. 17 at 9:33 PM

$EXOZ underwrote a $5.95 million offering of 592,270 shares and warrants, closing on June 9.

0 · Reply

NVDAMillionaire Jun. 10 at 12:44 PM

$EXOZ Really good write-up that perfectly summarizes EXOZ's present situation. So if you want to bring your EXOZ knowledge up to date or just discover EXOZ, this is required reading. https://everyticker.com/quote/EXOZ/analysis/exoz-99-conversion-efficiency-meets-100-funding-risk-at-exozymes-nasdaq-exoz

1 · Reply

B2iDigital Jun. 9 at 7:13 PM

eXoZymes (Nasdaq: $EXOZ ) announced the pricing of a public offering expected to generate approximately $5.3 million in gross proceeds, with funding intended to support development of its NCT program, continued R&D, and general corporate initiatives. For investors following eXoZymes, the announcement is significant because it provides additional capital to advance the company's AI-enabled exozyme platform and its efforts to scale production of high-value molecules for nutraceutical, pharmaceutical, and specialty chemical markets. eXoZymes is focused on using engineered enzymes operating outside living cells to manufacture complex molecules at commercial scale, an approach the company believes can overcome limitations associated with traditional biomanufacturing methods. Read the full announcement: https://exozymes.com/blog/fundraise-pricing-2026 eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1. Disclosure: This post is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation to purchase EXOZ or any other security. David Shapiro, CEO of B2i Digital, personally purchased shares of unrestricted EXOZ stock in the open market as part of B2i Digital's practice of investing alongside its Featured Companies. Investors should conduct their own due diligence and consult qualified financial and professional advisors before making any investment decisions. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

focafoca99 Jun. 8 at 6:44 PM

$EXOZ launched an underwritten offering of 592,270 shares and 292,135 warrants at $18 per unit, targeting roughly $5.3 million in proceeds.

0 · Reply

eXoZymes Jun. 8 at 1:05 PM

Announcing pricing of public offering of common stock and warrants: $EXOZ has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance and all shares of common stock and warrants that comprise the units are being issued as separate securities. The public offering price for a unit is $18.00. Full details here: https://exozymes.com/blog/fundraise-pricing-2026

0 · Reply

B2iDigital Jun. 5 at 6:03 PM

eXoZymes uses AI engineered enzymes to make natural molecules outside the living cell. Chris Marlett, Chairman of the Board of eXoZymes (Nasdaq: $EXOZ ), used a May 2026 investor presentation to lay out the company’s cell free biomanufacturing platform. The platform takes the enzymes that build complex natural molecules and runs them outside the living cell, which the company says yields high purity at commercial scale and reaches molecules that are hard to extract or synthesize otherwise. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Here is how Marlett described what the platform can now do: “...we are now proving that we can actually make these and scale them, which is a first, which was sort of the dream of synthetic biology but was never really delivered upon. And we’re demonstrating that we can manufacture them at scale. So many of these people are using synbio and making human gram quantities and we’re now demonstrating that we can deliver them in ton quantities. And the big benefit of what we’re doing is it’s super pure.” The presentation also covered: • A platform that takes enzymes out of the cell and evolves them to run at industrial scale, building on more than a decade of cell free research • A focus on natural molecules that are difficult to extract or synthesize through traditional methods • Technology transfer to a third party contract manufacturer to support scale up from lab to commercial volumes • The ability to engineer more potent and more bioavailable analogs of the molecules it produces Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology that uses AI engineered enzymes to convert feedstocks into high value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG

1 · Reply

Market Cap	40.53M
Revenue (ttm)	0.00
Net Income (ttm)	-9.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,000
Avg Vol	10,370
Day's Range	N/A - N/A
Shares Out	9.21M
Stochastic %K	0%
Beta	2.73
Analysts	Strong Buy
Price Target	N/A